131I治疗甲亢后甲减的综合预防和处理措施

李诗运

downloadPDF
文章导航 > 国际放射医学核医学杂志  > 2004,  28 > 4: (157-159)  
引用本文:
shu
Citation:
shu

131I治疗甲亢后甲减的综合预防和处理措施

  • 570311 海口, 海南省人民医院核医学科

  • 中图分类号: R581.2;R817.5

Synthetic prevention and treatment for hypothyroidism after rdioiodine therapy hyperthyroidism

  • Department of Nuclear Medicine, Hainan Province Hospital, Haikou 570311, China

  • CLC number: R581.2;R817.5

  • 摘要: 131I治疗甲状腺功能亢进症(甲亢)后甲状腺功能减退(甲减)是最重要的并发症,它制约着131I治疗甲亢的广泛应用。在实际工作中,应根据情况分析每一个病例的差异,运用现有的手段进行综合处理,包括131I治疗前的病例选择,敏感性估计,联合用药和治疗后的监测复查,早发甲减的及时处理。
    Abstract: Hypothyroidism is main complication after 131I therapy for hyperthyroidism in Graves' dis-ease. The hypothyroidism restricts its popular application that 131I treatment for Graves' disease. In clinic practice, different factors of every patient, involved case selection, sensitivity estimation, unite using medicine before 131I therapy are analysed, and synthetic measures for post treatment examination, transient hypothyroidism and permanent hypothyroidism after 131I therapy are discussed.
  • [1] Aizawa Y,Yoshida K,Kaise N.The development of transient hypothyroidism after iodine-131 treatment in hyperthyroid patients with Graves' disease prevalence,mechanism and prognosis[J].Clin Endocrinol,1997,46(1):1-5.
    [2] Yoshida K,Aizawa Y,KaiseN,et al.Role of thyroid-stimulating blocking antibody in patients who developed hypothyroidism within one year after 131I treatment for Graves' disease[J].Clin Endocrinol,1998,48(1):17-22.
    [3] Kraiem Z,Newfield RS.Grves'disease in childhood[J].J Pediatric Endocrinol Meyab,2001,14(3):229-243.
    [4] Pauwels EK,Smit JW,Slats A,et al.Health effects of the rapeutic use of I-131 in hyperthyroidism[J].Q J Nucl Med,2000,44(4):333-339.
    [5] Raham MA,Birrell G,Stewart H,et al.Successful radioiodine treatment in a 3 years old child with Grave's disease following antithyroid medication induced neutropenia[J].Arch Dis Child,2003,88(2):158-159.
    [6] Zdrojewicz Z,Gawry G,Tuckendlen R,et al.Thyrotoxicosis:indications and contraindications for radioiodine treatment[J].Wiad Lek,2000,53(5-6):346-354.
    [7] Khanna CM,Sankar R,Magdum M,et al.Early development of transient hypothyroidism after I-131 therapy for thyrotoxicosis[J].J Assoc Physician India,1998,46(3):268-272.
    [8] Kok SW,Smit JW,de Craen AJ,et al.Clinical outcome after standardized verus dosimetric radioiodine treatment of hyperthyroidism:an equivalence study[J].Nucl Med Commun,2000,21(11):1071-1078.
    [9] Nebesio TD,Siddiqui AR,Pescovitz OH,et al.Time course to hyperthyroidism after fixed-dose radioablation therapy of Graves' disease in children[J].J Pediatr,2002,141(1):99-103.
    [10] Allahabadia A,Daykin J,Sheppard MC,et al.Radioiodine treatment of hyperthyroidism prognostic factors for outcome[J].J Clin Endocrinol Metab,2001,86(8):3611-3617.
    [11] Bakken SC,Zanin DE,Zweers EJ.Treatment of hyperthyroidism caused by Graves' disease or toxic multinodular goiter by radioiodine:over 80% cure retrospectively after one calculated dose[J].Ned Tijdschr Geneeskd,2002,146(39):1837-1841.
    [12] Andrade VN,Gross JL,Maia AL,et al.The effect of methimazole pretreatment on the efficacy of radioiodine therapy in Grave's hyperthyroidism:one-year follow-up of a prospective randomized study[J].J Clin Endocrinol Metab,2001,86(8):3488-3489.
    [13] Haase A,Bahre M,Lauser I,et al.Radioiodine therapy in Graves' hyperthyroidism:determination of individual optium target dose[J].Exp Clin Endocrinol Diabetes,2000,108(2):133-137.
    [14] Kaplan MM,Meier DA,Dworkin HJ.Treatment of hyperthroidism with radioactive iodine[J].Endocrinol Metab clin North Am,1998,27(1):205-223.
    [15] Gomez JM,Gomez N,Amat M,et al.Hypothyroidism after iodine-131 or surgical therapy for Graves' disease hyperthyroidism[J].AnnEndocrinol,2000,61(3):184-191.
    [16] Cooper DS,Ridgway EC.Thoughts on prevention of thyroid disease in United States[J].Thyroid,2002,12(10):925-929.
  • [1] 陈再君 , 蒋宁一 . 131I治疗甲亢后致甲减的研究变迁. 国际放射医学核医学杂志, 2004, 28(4): 153-157.
    [2] 陈美言 , 李雪娜 , 李亚明 . Graves甲亢131I治疗后甲状腺功能的变化特点及其与治疗前抗体水平的关系. 国际放射医学核医学杂志, 2021, 45(1): 18-23. doi: 10.3760/cma.j.cn121381-202003035-000015
    [3] 陈丹云 , 静进 . 甲状腺功能亢进症治疗方法的选择. 国际放射医学核医学杂志, 2007, 31(4): 228-231.
    [4] 潘香颖 , 李慧贞 . 甲状腺功能亢进症伴肝功能受损的131I治疗疗效. 国际放射医学核医学杂志, 2009, 33(3): 179-180. doi: 10.3760/cma.j.issn.1673-4114.2009.03.013
    [5] 冯菲 , 赵德善 . 131I治疗青少年儿童甲状腺功能亢进症. 国际放射医学核医学杂志, 2009, 33(3): 171-174,183. doi: 10.3760/cma.j.issn.1673-4114.2009.03.011
    [6] 汤建林 , 李玉莹 , 高柳艳 , 唐秀萍 , 胡红永 . 甲状腺功能亢进症治疗方法的比较和选择. 国际放射医学核医学杂志, 2009, 33(3): 175-178. doi: 10.3760/cma.j.issn.1673-4114.2009.03.012
    [7] 董华 , 刘东海 , 李亚男 , 胡海龙 , 张遵城 . 肿瘤免疫治疗致甲状腺功能异常的99TcmO4− SPECT显像分析及文献复习. 国际放射医学核医学杂志, 2021, 45(9): 607-610. doi: 10.3760/cma.j.cn121381-202004017-00103
    [8] 郭坤 , 高蕊 , 于燕 , 刘岩 , 杨爱民 . 表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系. 国际放射医学核医学杂志, 2015, 39(1): 4-8. doi: 10.3760/cma.j.issn.1673-4114.2015.01.003
    [9] 苏莉 , 陈璟 , 赵明 . 131I治疗男性甲状腺亢进症周期性麻痹的临床观察:与抗甲状腺药物治疗比较. 国际放射医学核医学杂志, 2007, 31(6): 366-369.
    [10] 王长修 . 甲状腺功能亢进症患者再次131I治疗的给药剂量对比研究. 国际放射医学核医学杂志, 2009, 33(3): 182-183. doi: 10.3760/cma.j.issn.1673-4114.2009.03.016
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  1138
  • HTML全文浏览量:  125
  • PDF下载量:  3
出版历程
  • 收稿日期:  2003-11-02

131I治疗甲亢后甲减的综合预防和处理措施

  • 570311 海口, 海南省人民医院核医学科
  • 收稿日期: 2003-11-02

摘要: 131I治疗甲状腺功能亢进症(甲亢)后甲状腺功能减退(甲减)是最重要的并发症,它制约着131I治疗甲亢的广泛应用。在实际工作中,应根据情况分析每一个病例的差异,运用现有的手段进行综合处理,包括131I治疗前的病例选择,敏感性估计,联合用药和治疗后的监测复查,早发甲减的及时处理。

English Abstract

    全文HTML

参考文献 (16)

目录

    /

    返回文章
    返回

    版权所有©中华医学会   备案号：津ICP备15006720号-3

    地址：天津市南开区白堤路238号电话：86-22-58089989
    86-22-85682389    传真：022-87890607

    本系统由 北京仁和汇智信息技术有限公司 开发 技术支持： info@rhhz.net